ClinicalTrials.gg
Not yet recruitingNCT07858500RADIANCEUpdated Oct 28, 2026

Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)

An observational study in Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer and Metastatic Gastric Adenocarcinoma or Cancer, sponsored by Astellas Pharma Europe Ltd.. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Astellas Pharma Europe Ltd. (part of Astellas Pharma Inc) · Observational

How we know

Updated Oct 28, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Adenocarcinoma by Astellas Pharma Inc — 7 open to participants now, 9 under way, 4 of them phase 3. Adenocarcinoma · Astellas Pharma Inc.

Started
2027
the only one that year
Observational
2 of 12
2 open now
Registered
12th of 12
by date

Among the 12 studies in Adenocarcinoma by Astellas Pharma Inc, this one is the only one that started in 2027, is one of 2 observational ones, and was the 12th registered.

Adenocarcinoma

622 studies on the registry are indexed under Adenocarcinoma; 149 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

7 of the 12 studies in Adenocarcinoma by Astellas Pharma Inc are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 113 Adenocarcinoma studies recruiting now, 84 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Adenocarcinoma by Astellas Pharma Inc, or all of them as a file.
02

Study summary

There is an unmet medical need to treat people with advanced cancer in the stomach, or where the food pipe joins the stomach. These conditions are known as advanced gastric cancer or advanced gastroesophageal cancer (GEJ for short).

Zolbetuximab is an approved treatment for people with advanced stomach (gastric) cancer or advanced GEJ cancer. Some people with stomach or GEJ cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab works by attaching to the Claudin 18.2 protein in their tumor. This switches on the body's immune system to attack the tumor.

The main aim of the study is to collect information about zolbetuximab and other cancer treatments in people with advanced gastric or GEJ cancer. This includes safety information, how long people respond to treatment and how long people live for without their cancer getting worse.

This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the sponsor (Astellas).

This study will use information from European and Canadian health registries and databases to learn more about people with advanced gastric or GEJ cancers who used zolbetuximab and other cancer treatments. The entire study will last about 4 years.

03

Conditions studied

  • Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
  • Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
  • Metastatic Gastric Adenocarcinoma or Cancer
  • Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Keywords

  • Human Epidermal Growth Factor Receptor 2
  • HER2
  • HER2 Negative
  • Claudin-18 Isoform 2-positive
  • CLDN18.2+
  • zolbetuximab
  • IMAB362
  • Gastric cancer
  • Adenocarcinoma
  • Gastric adenocarcinoma
  • Gastroesophageal Junction cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Four registries or databases and at least 9 electronic medical record (EMR)-enabled sites will be used as data sources for this study. The study population will include participants with la/m HER2(-) and CLDN18.2(+) G/GEJ adenocarcinoma treated in 1L with zolbetuximab in combination with platinum-fluoropyrimidine doublet chemotherapy. A wider population of participants with la/m HER2(-) and CLDN18.2(+) G/GEJ adenocarcinoma, including those treated with other 1L treatments, will also be explored, as well as participants treated off-label with zolbetuximab.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohorts A, B and C:

  • Incident diagnosis of G/GEJ adenocarcinoma, as identified according to ICD-10 diagnosis codes (C16.x, C15.2, C15.5, C15.8, C15.9) and ICD for Oncology Third Edition (ICD-O-3) morphology codes (8140-8149, 8160-8162, 8190-8221, 8260-8337, 8350 8551, 8570-8576, 8940-8941) or data source equivalent.
  • At least 18 years of age at the date of 1L treatment initiation.

Cohorts A and B:

  • Evidence of unresectable stage 3 or stage 4 disease.
  • Evidence of (-) tumor any time prior to and including the date of 1L treatment initiation.
  • Evidence of CLDN18.2-positive tumor, defined as ≥75% of tumor cells showing moderate (2+) or strong (3+) membranous staining by IHC, assessed prior to or on the date of 1L treatment initiation.

Cohort A only:

  • 1L treatment with zolbetuximab in combination with platinum-fluoropyrimidine doublet chemotherapy which begins during the patient enrolment period.

Cohort B only:

  • 1L treatment that does not include zolbetuximab which begins during the patient enrolment period.

Cohort C only:

  • Zolbetuximab administered during the patient enrolment period under any of the following off-label conditions:

    • NOT delivered in 1L for la/m disease and/or
    • NOT delivered in combination with platinum-fluoropyrimidine doublet, and/or
    • Delivered in combination with any systemic anti-cancer treatment that is not platinum-fluoropyrimidine doublet, and/or
    • NOT delivered to a patient with evidence of HER2(-) tumor any time prior to and including the date of zolbetuximab initiation, and/or
    • NOT delivered to a patient with evidence of CLDN18.2(+)-positive tumor, defined as ≥75% of tumor cells demonstrating moderate (2+) or strong (3+) membranous staining by IHC, assessed prior to or on the date of zolbetuximab initiation.

Exclusion criteria

Exclusion Criteria:

Cohorts A, B and C:

  • Evidence of any other primary in the 5 years prior to and including the index date, as identified according to ICD-10 codes or data source equivalent and excluding non-melanoma skin cancer (ICD-10 code C44.x).

Cohort A only:

  • Evidence that 1L treatment with zolbetuximab was received as part of a clinical trial.

Cohort B only:

  • Evidence that 1L treatment was received as part of a clinical trial.

Cohort C only:

  • Evidence that zolbetuximab was received as part of a clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort A: zolbetuximab with platinum-fluoropyrimidine chemotherapy

    Participants with human epidermal growth factor receptor 2-negative (HER2\[-\]) and claudin-18 isoform 2-positive (CLDN18.2\[+\]) locally advanced unresectable or metastatic (la/m) gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who received first-line (1L) treatment with zolbetuximab in combination with platinum-fluoropyrimidine doublet chemotherapy.

    Drug: Zolbetuximab Exposure · Drug: Platinum-based Chemotherapy Exposure · Drug: Fluoropyrimidine-based Chemotherapy Exposure

  • Cohort B: 1L treatment which did not contain zolbetuximab

    Participants with HER2(-) and CLDN18.2(+) la/m G/GEJ adenocarcinoma who received 1L treatment which did not contain zolbetuximab.

    Drug: 1L Treatment Not Containing Zolbetuximab Exposure

  • Cohort C: off-label treatment with zolbetuximab

    Participants with G/GEJ adenocarcinoma who received off-label treatment with zolbetuximab.

    Drug: Zolbetuximab Exposure

Interventions

  • DrugZolbetuximabStudies of ZolbetuximabZolbetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Real-world exposure to zolbetuximab.

    Also known as: Vyloy, IMAB362

  • DrugPlatinum-based Chemotherapy Exposure

    Real-world exposure to platinum-based chemotherapy.

  • Drug1L Treatment Not Containing Zolbetuximab Exposure

    Real-world exposure to 1L treatment not containing zolbetuximab.

  • DrugFluoropyrimidine-based Chemotherapy Exposure

    Real-world exposure to fluoropyrimidine-based chemotherapy.

06

What researchers measure

Primary outcomes

  1. Cohort A: real-world overall survival (rwOS)

    The length of time a participant survives, from the point of initiating 1L treatment, using data retrieved retrospectively. Death due to any case will be considered in the definition of rwOS.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  2. Cohort A: real-world progression-free survival (rwPFS)

    The length of time a participant survives without their cancer progressing, from the point of initiating 1L treatment, using data retrieved retrospectively. Progression will be identified according to clinical notes, radiology reports or pathology reports, and death due to any cause will be considered in the definition of rwPFS.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  3. Cohort A: real-world time to next treatment (rwTTNT)

    The length of time until a participant initiates second-line (2L) treatment, from the point of initiating 1L treatment, using data retrieved retrospectively. Death due to any cause will be considered a competing event.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  4. Cohort A: real-world time to next treatment or death (rwTTNTD)

    The length of time a participant survives without initiating 2L treatment, from the point of initiating 1L treatment, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  5. Cohort A: real-world time to progression (rwTTP)

    The length of time until a participant's cancer progresses, from the point of initiating 1L treatment, using data retrieved retrospectively. Progression will be identified according to clinical notes, radiology reports or pathology reports. Death due to any cause will be considered a competing event.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  6. Cohort A: real-world duration of response (rwDOR)

    The length of time a participant responds to 1L treatment without dying or their cancer progressing, from the first record of complete or partial response to 1L treatment, using data retrieved retrospectively. Response will be identified as per clinical assessment, and progression will be identified according to clinical notes, radiology reports or pathology reports. Death due to any cause will be considered in the definition of rwDOR.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  7. Cohort A: real-world response rate (rwRR)

    The percentage of participants who have responded to 1L treatment within 12 months following initiation of 1L treatment, using data retrieved retrospectively. Complete or partial response will be identified as per clinical assessment.

    Time frame: From the point of initiating 1L treatment, assessed up to 12 months

  8. Cohort A: real-world disease control rate (rwDCR)

    The percentage of participants who have either responded to 1L treatment or have achieved stable disease within 12 months following initiation of 1L treatment, using data retrieved retrospectively. Complete response, partial response and stable disease will be identified as per clinical assessment.

    Time frame: From the point of initiating 1L treatment, assessed up to 12 months

  9. Cohort A: real-world tumor growth rate (rwTGR) prior to 1L treatment

    The percentage change in tumor size over the period of time between the second to last and last tumor size record prior to index date. rwTGR will be assessed prior to initiating 1L treatment based on medical history available, using data retrieved retrospectively. Tumor size will be estimated as the sum of the longest diameters of all recorded measurable lesions (primary or metastatic).

    Time frame: Day 1

  10. Cohort A: rwTGR

    The percentage change in tumor size from prior to initiation of 1L treatment, over a period of time. rwTGR will be assessed during 1L treatment using data retrieved retrospectively. Tumor size will be estimated as the sum of the longest diameters of all recorded measurable lesions (primary or metastatic).

    Time frame: From point of initiating 1L treatment, assessed up to 4 years

  11. Cohort A: number of records of specified adverse events (AEs)

    Specified AEs are inclusive of nausea, vomiting, decreased appetite, diarrhea, peripheral sensory neuropathy, anemia, constipation, decreased neutrophil count, fatigue, asthenia, abdominal pain, stomatitis, weight decrease, aspartate aminotransferase increase, platelet count decrease, hypoalbuminemia, white blood cell count decrease and neutropenia. An AE is defined as any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  12. Cohort A: duration of specified AEs

    The total length of time a participant has a record of experiencing a specified AE occurrence during 1L treatment, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  13. Cohort A: time to first specified AE record

    The length of time until a participant experiences each of the specified AEs above during 1L treatment, from the point of initiating 1L treatment, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  14. Cohort A: number of participants with serious adverse events (SAEs)

    SAEs are any signs, symptoms, or diseases which lead to inpatient hospitalization, treatment discontinuation and/or cause death and which are experienced during 1L treatment. Events will be identified from participant records retrieved retrospectively; there is no requirement for the events to be explicitly linked to 1L treatment.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  15. Cohort A: number of SAEs experienced per participant

    SAEs are any signs, symptoms, or diseases which lead to inpatient hospitalization, treatment discontinuation and/or cause death and which are experienced during 1L treatment. Events will be identified from participant records retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  16. Cohort A: number of specific SAE

    SAEs are any signs, symptoms, or diseases which lead to inpatient hospitalization, treatment discontinuation and/or cause death and which are experienced during 1L treatment. Events will be identified from participant records retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  17. Cohort A: number of records per participant of specific SAE

    SAEs are any signs, symptoms, or diseases which lead to inpatient hospitalization, treatment discontinuation and/or cause death and which are experienced during 1L treatment. Events will be identified from participant records retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  18. Cohort A: time to first SAE record

    The length of time until a participant experiences a SAE during 1L treatment, from the point of initiating 1L treatment, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  19. Cohort A: number of participants with inpatient hospitalizations

    Number of inpatient hospitalizations during 1L treatment, as recorded up to end of 1L treatment (inclusive), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  20. Cohort A: number of inpatient hospitalizations with ICU stay per participant

    Number of inpatients hospitalizations per participant with ICU stay during 1L treatment, as recorded from index date (inclusive) to end of 1L treatment (inclusive), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  21. Cohort A: number of inpatient hospitalizations with admission via accident and emergency (A&E) per participant

    Number of inpatients hospitalizations per participant with admission via A\&E during 1L treatment, as recorded from index date (inclusive) to end of 1L treatment (inclusive), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  22. Cohort A: duration of inpatient hospitalizations

    Average duration (in days) of inpatient hospitalization during 1L treatment, as derived according to the difference between admission and discharge dates for all inpatient hospitalizations from index date (inclusive) to end of 1L treatment (inclusive), using data retrieved retrospectively. One participant may experience more than one hospitalization and may contribute multiple times for this variable.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  23. Cohort A: primary diagnoses associated with inpatient hospitalizations

    Primary diagnoses associated with inpatient hospitalizations during 1L treatment, as recorded using diagnosis codes (International Classification of Diseases, 10th revision \[ICD-10\] codes, or equivalent as available in each data source), using data retrieved retrospectively. A participant can have multiple diagnoses per inpatient hospitalization and multiple inpatient hospitalization.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  24. Cohort A: number of participants receiving at least one antiemetic

    Number of participants with prescriptions or dispensations of any antiemetic drug from 1 day before index date (inclusive) to the end of 1L treatment (inclusive), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  25. Cohort A: number of antiemetics prescribed or dispensed to participants

    Number of records of prescriptions or dispensations of any antiemetic drug from 1 day before index date (inclusive) to the end of 1L treatment (inclusive), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  26. Cohort A: time to prescription or dispensation of any antiemetic drugs

    Time from index date to first prescription or dispensation of antiemetic drugs during 1L treatment, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  27. Cohort A: type of antiemetic drug received immediately prior to 1L treatment

    Type of antiemetic drug prescribed immediately prior to 1L treatment, as recorded 1 day before index date (inclusive) based on medical history available, using data retrieved retrospectively.

    Time frame: Day 1

  28. Cohort A: type of antiemetic drug received

    Type of antiemetic drug prescribed during 1L treatment, as recorded to the end of 1L treatment (inclusive), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  29. Cohort A: antiemetic drugs received immediately prior to 1L treatment

    Antiemetic drugs prescribed immediately prior to 1L treatment, as recorded 1 day before index date (inclusive) based on medical history available, using data retrieved retrospectively.

    Time frame: Day 1

  30. Cohort A: antiemetic drugs received

    Antiemetic drugs prescribed during 1L treatment, as recorded to the end of 1L treatment (inclusive), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

Secondary outcomes

  1. Cohort A demographic characteristics: age

    Age as recorded or derived based on participant birth date, date of diagnosis, and 1L treatment initiation, using data retrieved retrospectively.

    Time frame: Day 1

  2. Cohort A demographic characteristics: sex

    Sex as recorded at any time in participant records (female, male, or missing/unknown), using data retrieved retrospectively.

    Time frame: Day 1

  3. Cohort A demographic characteristics: race or ethnicity

    Ethnicity or race (Asian, black, mixed, or multiple ethnic groups, white, other ethnic group, or missing/unknown), as recorded at any time in participant records, using data retrieved retrospectively.

    Time frame: Day 1

  4. Cohort A demographic characteristics: country

    Country of treatment site, as derived according to the country in which the data source is located, using data retrieved retrospectively.

    Time frame: Day 1

  5. Cohort A demographic characteristics: socioeconomic status

    Socioeconomic status as derived from available variables recorded any time prior to an including the index date, using data retrieved retrospectively.

    Time frame: Day 1

  6. Cohort A clinical characteristics: alcohol consumption

    Alcohol consumption, as recorded any time between diagnosis of la/m G/GEJ adenocarcinoma (inclusive) and index date (inclusive), using data retrieved retrospectively.

    Time frame: Day 1

  7. Cohort A clinical characteristics: smoking status

    Smoking status, as recorded any time between diagnosis of la/m G/GEJ adenocarcinoma (inclusive) and index date (inclusive), using data retrieved retrospectively.

    Time frame: Day 1

  8. Cohort A clinical characteristics: body mass index (BMI)

    BMI (in kg/m\^2) at index date, as recorded or as derived according to the formula weight/height using the closest measurements of weight (kg) and height (m) which are recorded prior to and including the index date. Weight measurements must be no more than 1 year prior to the index date; height measurements will be considered from the start of participant records (18.5 = underweight, 18.5 to \<25.0 = normal weight, 25.0 to \<30 = pre-obesity, ≥30 = obesity, or missing/unknown), using data retrieved retrospectively.

    Time frame: Day 1

  9. Cohort A clinical characteristics: disease stage (TNM)

    Disease stage at initial diagnosis of G/GEJ adenocarcinoma and at la/m diagnosis of G/GEJ adenocarcinoma, as recorded according to 7th or 8th American Joint Committee on Cancer (AJCC) TNM classification (TXNXMX), using data retrieved retrospectively.

    Time frame: Day 1

  10. Cohort A clinical characteristics: disease stage (numeric)

    Disease stage at initial diagnosis of G/GEJ adenocarcinoma and at la/m diagnosis of G/GEJ adenocarcinoma, as recorded according to the numeric classification (0, I, II, III, IV, or missing/unknown), using data retrieved retrospectively.

    Time frame: Day 1

  11. Cohort A clinical characteristics: tumor grade

    Histological grade of primary tumor at initial diagnosis of G/GEJ adenocarcinoma, as recorded (1 = low grade, 2 = moderate grade, 3 = high grade, or missing/unknown), using data retrieved retrospectively.

    Time frame: Day 1

  12. Cohort A clinical characteristics: histotype at initial diagnosis

    Histotype of primary tumor at initial diagnosis of G/GEJ adenocarcinoma, as recorded using the Lauren classification (intestinal, diffuse, mixed, other, missing/unknown), using data retrieved retrospectively.

    Time frame: Day 1

  13. Cohort A clinical characteristics: site of primary tumor

    Site of primary tumor at initial diagnosis of G/GEJ adenocarcinoma, as recorded (gastric or gastroesophageal junction), using data retrieved retrospectively.

    Time frame: Day 1

  14. Cohort A clinical characteristics: size of primary tumor at initial diagnosis

    Size (in mm) of primary tumor at initial diagnosis of G/GEJ adenocarcinoma, as recorded, using data retrieved retrospectively.

    Time frame: Day 1

  15. Cohort A clinical characteristics: Eastern Cooperative Oncology Group (ECOG) performance status

    ECOG performance status at index date, as recorded from la/m diagnosis (inclusive) to index date (inclusive), using data retrieved retrospectively. Any participant with a score of 5 (i.e., dead) will have their value reported as missing/unknown. Lower scores represent an increased ability to carry out the daily living activities.

    Time frame: Day 1

  16. Cohort A clinical characteristics: Charlson Comorbidity Index (CCI)

    CCI score at index date, as derived according to medical diagnoses, including comorbid conditions, recorded using ICD-10 codes or data source equivalent any time prior to and including the index date, using data retrieved retrospectively (0, 1, 2, 3, ≥4, or missing/unknown) where lower scores represent lower comorbidity.

    Time frame: Day 1

  17. Cohort A clinical characteristics: comorbidities

    Comorbidities (hypertension, diabetes mellitus, ulcerative digestive tract disease, dyslipidemia, other gastrointestinal disease, cardiovascular disease, and chronic kidney disease) recorded (yes, no) prior to and including index date, defined by 1 or more ICD-10 codes, using data retrieved retrospectively.

    Time frame: Day 1

  18. Cohort A clinical characteristics: number of metastatic sites

    Number of metastatic sites at index date, as derived from ICD-10 codes or data source equivalent recorded any time prior to and including the index date (0, 1, 2, 3, …), using data retrieved retrospectively.

    Time frame: Day 1

  19. Cohort A clinical characteristics: number of metastatic lesions

    Number of metastatic lesions at index date, as derived from participant records any time prior to and including the index date (0, 1, 2, 3, …), using data retrieved retrospectively.

    Time frame: Day 1

  20. Cohort A clinical characteristics: location of metastatic sites

    Metastatic sites (liver, lymph node, lung, peritoneum, bone, large intestine or rectum, other specified, or other unspecified site) recorded (yes, no) defined by 1 or more ICD-10 codes or data source equivalent from diagnosis of la/m disease until index date, using data retrieved retrospectively.

    Time frame: Day 1

  21. Cohort A clinical characteristics: systemic anti-cancer therapy (SACT)

    SACT received prior to index date, as recorded from initial diagnosis of G/GEJ adenocarcinoma (any stage, inclusive) until index date (exclusive), using data retrieved retrospectively.

    Time frame: Day 1

  22. Cohort A clinical characteristics: type/intention of SACT

    Type/intention of SACT (neoadjuvant SACT only, adjuvant SACT only, both neoadjuvant and adjuvant SACT \[perioperative\], no prior SACT) received prior to index date, as derived according to the dates of SACT and surgery records from initial diagnosis of G/GEJ adenocarcinoma (any stage, inclusive) until index date (exclusive), using data retrieved retrospectively.

    Time frame: Day 1

  23. Cohort A clinical characteristics: neoadjuvant SACT regimen

    Neoadjuvant SACT regimen received prior to index date, as recorded or derived, using data retrieved retrospectively.

    Time frame: Day 1

  24. Cohort A clinical characteristics: adjuvant SACT regimen

    Adjuvant SACT regimen received prior to index date, as recorded or derived, using data retrieved retrospectively.

    Time frame: Day 1

  25. Cohort A clinical characteristics: perioperative SACT regimen

    Perioperative SACT regimen received prior to index date, as recorded or derived, using data retrieved retrospectively.

    Time frame: Day 1

  26. Cohort A clinical characteristics: chemoradiation therapy

    Chemoradiation received prior to index date, as recorded or derived according to records of chemotherapy and radiation therapy which overlap and which are recorded between the date of initial diagnosis of G/GEJ adenocarcinoma (inclusive, any stage) until index date (exclusive), using data retrieved retrospectively.

    Time frame: Day 1

  27. Cohort A clinical characteristics: chemoradiation therapy regimen

    Chemoradiation therapy regimen received prior to index date, as recorded or derived, using data retrieved retrospectively.

    Time frame: Day 1

  28. Cohort A clinical characteristics: radiation therapy

    Radiation therapy received prior to index date, as recorded from the date of initial diagnosis of G/GEJ adenocarcinoma (inclusive, any stage) until index date (exclusive), using data retrieved retrospectively.

    Time frame: Day 1

  29. Cohort A clinical characteristics: type of radiation therapy

    Type of radiation therapy received prior to index date, as recorded, using data retrieved retrospectively.

    Time frame: Day 1

  30. Cohort A clinical characteristics: prior gastrectomy

    Gastrectomy received prior to index date, as recorded from the date of initial diagnosis of G/GEJ adenocarcinoma (inclusive, any stage) until index date (exclusive) (yes or no), using data retrieved retrospectively.

    Time frame: Day 1

  31. Cohort A clinical characteristics: type of gastrectomy

    Type of gastrectomy received prior to index date, as recorded (partial, total, other, no gastrectomy), using data retrieved retrospectively.

    Time frame: Day 1

  32. Cohort A clinical characteristics: time from gastrectomy to index date

    Among those who have received gastrectomy, time from gastrectomy until index, as derived from the date of gastrectomy and the index date, using data retrieved retrospectively.

    Time frame: Day 1

  33. Cohort A biomarker characteristics: HER2 expression level

    HER2 expression level at index date, as recorded (none \[IHC 0\], low \[IHC 1+\], indeterminate \[IHC 2+\], high \[IHC 3+\], or missing/unknown), using data retrieved retrospectively. Specimens from any primary cancer or metastatic biopsy sites are allowed.

    Time frame: Day 1

  34. Cohort A biomarker characteristics: CLDN18.2 status

    CLDN18.2 status at index date, defined as moderate (IHC 2+) to strong (IHC 3+) membranous staining in ≥75% of tumor cells, as recorded any time prior to and including the index date (negative, positive or not tested), using data retrieved retrospectively.

    Time frame: Day 1

  35. Cohort A biomarker characteristics: CLDN18.2 expression level

    CLDN18.2 expression level at index date, as recorded (moderate to strong staining in 0% to \<25% of cells, moderate to strong staining in ≥25% and \<50% of cells, moderate to strong staining in ≥50% and \<75% of cells, moderate to strong staining in ≥75% of cells, missing/unknown, or not tested), using data retrieved retrospectively.

    Time frame: Day 1

  36. Cohort A biomarker characteristics: programmed death-ligand 1 (PD-L1) tested

    PD-L1 tested at index date, as recorded any point prior to and including the index date (yes or no), using data retrieved retrospectively.

    Time frame: Day 1

  37. Cohort A biomarker characteristics: combined positive score (CPS)

    CPS at index date, as recorded any point prior to and including the index date (\<1, 1 to \<5, 5 to \<10, ≥10, or not tested), using data retrieved retrospectively.

    Time frame: Day 1

  38. Cohort A biomarker characteristics: tumor area positivity (TAP)

    TAP at index date, as recorded any point prior to and including the index date (\<1, 1 to \<5, 5 to \<10, ≥10, or not tested), using data retrieved retrospectively.

    Time frame: Day 1

  39. Cohort A biomarker characteristics: tumor proportion score (TPS)

    TPS at index date, as recorded any point prior to and including the index date (\<1%, 1 to \<50%, ≥50%, not tested), using data retrieved retrospectively.

    Time frame: Day 1

  40. Cohort A biomarker characteristics: mismatch repair deficient (dMMR) status

    dMMR status at index date, as derived from IHC or MSI testing results any time prior to and including the index date (deficient, proficient or not tested), using data retrieved retrospectively.

    Time frame: Day 1

  41. Cohort A biomarker characteristics: Epstein-Barr virus (EBV) status

    EBV status at index date, as recorded any point prior to and including the index date (EBV-positive, EBV-negative or not tested), using data retrieved retrospectively.

    Time frame: Day 1

  42. Cohort A biomarker characteristics: Fibroblast Growth Factor Receptor 2b (FGFR2b) expression levels

    FGFR2b expression level at index date, as recorded any point prior to and including the index date (none, \<10% of tumor cells with moderate/strong staining \[IHC 2+ or 3+\], ≥10% of tumor cells with moderate/strong staining \[IHC 2+ or 3+\], or not tested), using data retrieved retrospectively.

    Time frame: Day 1

  43. Cohort A biomarker testing patterns: immunohistochemistry (IHC) platform

    IHC platform used to determine PD-L1 and CLDN18.2 status at index date, as recorded any point prior to and including the index date (Ventana, Dako, Leica, other, missing/unknown, or not tested), using data retrieved retrospectively.

    Time frame: Day 1

  44. Cohort A biomarker testing patterns: IHC antibody clone

    Antibody clone used for IHC testing to determine PD-L1 (22C3, 28-8, SP263, other, missing/unknown, or not tested) and CLDN18.2 (43-14A, 34H14L15, 14F8, 43-14A, LS-B16145, other, missing/unknown, not tested) status at index date, as recorded, using data retrieved retrospectively.

    Time frame: Day 1

  45. Cohort A biomarker testing patterns: number of biomarker tests performed

    Number of HER2 and CLDN18.2 tests prior to and including index date, as recorded (1, 2, 3, …, or missing/unknown), using data retrieved retrospectively.

    Time frame: Day 1

  46. Cohort A biomarker testing patterns: number of positive biopsy samples used for determination of biomarker status

    Number of positive biopsy samples used for determination of HER2 and CLDN18.2 status at index date, as recorded (1, 2, 3, …, missing/unknown, or not tested), using data retrieved retrospectively.

    Time frame: Day 1

  47. Cohort A biomarker testing patterns: relative timing of tests

    Time from HER2 test request until CLDN18.2 test request and from PD-L1 test request until CLDN18.2 test request, as derived (CLDN18.2 test request prior to HER2 test request, HER2 test request prior to CLDN18.2 test request, or simultaneous; CLDN18.2 test request prior to PD-L1 test request, PD-L1 test request prior to CLDN18.2 test request, or simultaneous), using data retrieved retrospectively.

    Time frame: Day 1

  48. Cohort A biomarker testing patterns: time from test to treatment initiation

    Time from most recent biomarker test request and report until zolbetuximab initiation, using data retrieved retrospectively.

    Time frame: Day 1

  49. Cohort A treatment patterns: 1L regimen received

    1L treatment regimen received, as recorded or as derived according to a line of therapy algorithm, using data retrieved retrospectively.

    Time frame: Day 1

  50. Cohort A treatment patterns: duration of 1L treatment

    Duration of 1L treatment, measured from the index date to the earliest of date of 1L discontinuation (i.e., discontinuation of all components of 1L), date of initiation of 2L treatment, date of death due to any case or start of new treatment), date of loss to follow-up or end of study period, plus 1 day, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  51. Cohort A treatment patterns: real-world time to treatment discontinuation (rwTTD)

    Time from index date to the date of 1L discontinuation, using data retrieved retrospectively. Participants who did not discontinue 1L will be censored at the earliest of date of death due to any cause, date of loss to follow-up or end of study period, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  52. Cohort A treatment patterns: reasons for 1L treatment discontinuation

    Reasons for discontinuation of 1L treatment, as recorded (disease progression, death, toxicity, adverse reaction, other, multiple reasons, missing/ unknown, did not discontinue treatment), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  53. Cohort A treatment patterns: dosing schedule

    Dosing schedule of 1L zolbetuximab treatment, as recorded or derived based on administration dates and recorded 1L treatment doses (every 2 weeks, every 3 weeks, other, or missing/ unknown), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  54. Cohort A treatment patterns: number of participants with dose modifications

    Number of participants with at least one recorded 1L dose modification relative to the initial dose (yes or no), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  55. Cohort A treatment patterns: reason for dose modification

    Reason for the first dose modification during 1L treatment as recorded (AE, SAE, disease progression, participant factors \[e.g., weight loss\], drug interactions, other, multiple reasons, missing/unknown, no dose modification), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  56. Cohort A treatment patterns: direction of dose modification

    The direction of change (increase, decrease, both increase and decrease \[regardless of order\], no dose modification) in 1L dose level, as derived per participant, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  57. Cohort A treatment patterns: number of dose modifications per participant

    Total number of dose modifications experienced during 1L treatment per participant, as recorded, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  58. Cohort A treatment patterns: time to first dose modification

    Time from index date to the date of first recorded 1L dose modification. Participants without any recorded dose modification in 1L will be censored at the earliest of end of 1L, date of death due to any cause, date of loss to follow-up or end of study period, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  59. Cohort A treatment patterns: number of dose interruptions

    Any record of an interruption in dosage during 1L treatment, as recorded or derived according to observed gaps between treatment cycles (yes or no), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  60. Cohort A treatment patterns: reason for dose interruption

    Reason for first dose interruption during 1L treatment, as recorded (AE, disease progression, participant factors \[e.g., weight loss\], drug interactions, other, multiple reasons, missing/unknown, no dose interruption), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  61. Cohort A treatment patterns: number of dose interruptions per participant

    Total number of dose interruptions experienced per participant during 1L treatment, as recorded, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  62. Cohort A treatment patterns: time to first dose interruption

    Time from index date to the date of first recorded 1L dose interruption. Participants without any recorded dose interruption in 1L will be censored at the earliest of end of 1L, date of death due to any cause, date of loss to follow-up or end of study period, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  63. Cohort A treatment patterns: number of infusion rate reductions

    Reduction in infusion rate of intravenous (IV) 1L treatment, as recorded, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  64. Cohort A treatment patterns: reason for infusion rate reduction

    Reason for first infusion rate reduction during 1L treatment, as recorded, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  65. Cohort A treatment patterns: time to first administration with infusion rate reduction

    Time from index date to the date of first administration with infusion rate reduction during 1L. Participants without any recorded infusion rate reduction in 1L will be censored at the earliest of end of 1L, date of death due to any cause, date of loss to follow-up or end of study period, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  66. Cohort A treatment patterns: infusion interruption

    Any record of interruption in IV 1L treatment (e.g. temporary or permanent halting of an IV infusion), any time from index date (inclusive) to end of 1L treatment (inclusive) (yes, no record), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  67. Cohort A treatment patterns: reason for infusion interruption

    Reason for first infusion interruption during 1L treatment, as recorded (AE, participant factors, other, multiple reasons, missing/unknown, no infusion interruption), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  68. Cohort A treatment patterns: time to first infusion interruption

    Time from index date to the date of first administration with infusion interruption during 1L. Participants without any recorded infusion rate reduction in 1L will be censored at the earliest of end of 1L, date of death due to any cause, date of loss to follow-up or end of study period, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  69. Cohort A treatment patterns: relative dose intensity

    Relative dose intensity of zolbetuximab for each 1L treatment cycle, as derived from the actual dosage received divided by the planned dosage, using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  70. Cohort A treatment patterns: BMI at each 1L treatment cycle

    BMI at each 1L treatment cycle, as recorded or derived from the closest measurements of height and weight (kg/m\^2). Weight measurements must be recorded from initiation of the previous treatment cycle (exclusive) to initiation of the current treatment cycle (inclusive); height measurements will be considered from the start of participant records (18.5 = underweight, 18.5 to \<25.0 = normal weight, 25.0 to \<30 = pre-obesity, ≥30 = obesity, or missing/unknown), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  71. Cohort A treatment patterns: body surface area (BSA) at each 1L treatment cycle

    BSA at each 1L treatment cycle, as recorded or derived according to the formula 0.007184\*height 0.725\* weight 0.425 using the closest measurements of weight (kg) and height (m). Weight measurements must be recorded from initiation of the previous treatment cycle (exclusive) to initiation of the current treatment cycle (inclusive); height measurements will be considered from the start of participant records (1.5 to \<1.75, 1.75 to \<2.00, 2.00 to \<2.25, 2.25 to \<2.5, \>=2.5, or missing/unknown), using data retrieved retrospectively.

    Time frame: From the point of initiating 1L treatment, assessed up to 4 years

  72. Cohort A treatment patterns: 2L treatment regimen received

    2L treatment regimen received (mono- or combination therapy), as recorded or derived according to a line of therapy algorithm (mono- or combination therapy), using data retrieved retrospectively.

    Time frame: From the point of initiating 2L treatment, assessed up to 4 years

07

Study locations

1 site
  • Research Institution
    Alberta, Canada
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Jun 2029, 28 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Jan 31, 2027was Oct 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 31, 2026→Jan 31, 2027
Oct 28, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 28, 2026
    Start date Oct 31, 2026→Jan 31, 2027
    + 1 other change: verification date
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858500
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Jan 31, 2027 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Astellas Pharma Europe Ltd.
Contact
Astellas.registration@astellas.com
+1-800-888-7704
Central Contact
study director · Astellas Pharma Europe Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion